[go: up one dir, main page]

RU2001133455A - Essentially oil-free compositions comprising cyclosporin - Google Patents

Essentially oil-free compositions comprising cyclosporin

Info

Publication number
RU2001133455A
RU2001133455A RU2001133455/14A RU2001133455A RU2001133455A RU 2001133455 A RU2001133455 A RU 2001133455A RU 2001133455/14 A RU2001133455/14 A RU 2001133455/14A RU 2001133455 A RU2001133455 A RU 2001133455A RU 2001133455 A RU2001133455 A RU 2001133455A
Authority
RU
Russia
Prior art keywords
composition according
composition
capsule
cyclosporin
fill
Prior art date
Application number
RU2001133455/14A
Other languages
Russian (ru)
Other versions
RU2249461C2 (en
Inventor
Михаэль АМБЮЛЬ
Барбара ЛЮККЕЛЬ
Барбара ХЭБЕРЛИН
Армин МАЙНЦЕР
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9912476.0A external-priority patent/GB9912476D0/en
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2001133455A publication Critical patent/RU2001133455A/en
Application granted granted Critical
Publication of RU2249461C2 publication Critical patent/RU2249461C2/en

Links

Claims (14)

1. Содержащая циклоспорин композиция в форме капсулы, включающая эфир жирной кислоты и полиоксиэтиленсорбитана, продукт реакции природного или гидрогенизированного касторового масла и этиленоксида, эфир жирной кислоты и сорбитана и этанол.1. A cyclosporin-containing capsule composition comprising a fatty acid ester and polyoxyethylene sorbitan, a reaction product of natural or hydrogenated castor oil and ethylene oxide, a fatty acid ester of sorbitan and ethanol. 2. Содержащая циклоспорин композиция в форме капсулы, включающая: (а) гидрофильное поверхностно-активное вещество, (б) липофильный компонент, (в) липофильное поверхностно-активное вещество и (г) этанол, отличающаяся присутствием эфира жирной кислоты и полиоксиэтиленсорбитана, продукта реакции природного или гидрогенизированного касторового масла и этиленоксида, и эфира жирной кислоты и сорбитана.2. A capsule-containing composition containing cyclosporin, comprising: (a) a hydrophilic surfactant, (b) a lipophilic component, (c) a lipophilic surfactant, and (d) ethanol, characterized by the presence of a fatty acid ester and polyoxyethylene sorbitan, a reaction product natural or hydrogenated castor oil and ethylene oxide, and a fatty acid ester and sorbitan. 3. Желатиновая капсула с твердым покрытием, содержащая композицию по п.1 или 2.3. Hard gelatin capsule containing the composition according to claim 1 or 2. 4. Композиция по пп.1, 2 или 3, включающая циклоспорин в количестве 1-20% в пересчете на массу композиции для заполнения капсулы.4. The composition according to claims 1, 2 or 3, comprising cyclosporine in an amount of 1-20%, calculated on the weight of the composition to fill the capsule. 5. Композиция по любому из пп.2-4, включающая липофильный компонент в количестве 5-35% в пересчете на массу композиции для заполнения капсулы.5. The composition according to any one of claims 2 to 4, comprising a lipophilic component in an amount of 5-35%, calculated on the weight of the composition to fill the capsule. 6. Композиция по любому из пп.2-5, включающая гидрофильное поверхностно-активное вещество в количестве 25-70% в пересчете на массу композиции для заполнения капсулы.6. The composition according to any one of paragraphs.2-5, comprising a hydrophilic surfactant in an amount of 25-70%, calculated on the weight of the composition to fill the capsule. 7. Композиция по любому из пп.2-6, включающая липофильное поверхностно-активное вещество в количестве 5-35% в пересчете на массу композиции для заполнения капсулы.7. The composition according to any one of claims 2 to 6, comprising a lipophilic surfactant in an amount of 5-35%, calculated on the weight of the composition to fill the capsule. 8. Композиция по любому из пп.1-7, включающая этанол в количестве 1-20% в пересчете на массу композиции для заполнения капсулы.8. The composition according to any one of claims 1 to 7, comprising ethanol in an amount of 1-20%, calculated on the weight of the composition to fill the capsule. 9. Композиция по любому из предыдущих пунктов, в которой циклоспорин представляет собой циклоспорин А.9. The composition according to any one of the preceding paragraphs, in which cyclosporin is cyclosporin A. 10. Композиция по любому из предыдущих пунктов, в которой присутствует дополнительный гидрофильный компонент.10. The composition according to any one of the preceding paragraphs, in which there is an additional hydrophilic component. 11. Способ уменьшения вариабельности уровней биологической доступности циклоспорина для пациента при лечении циклоспорином, предусматривающий введение пероральным путем композиции по любому из предыдущих пунктов.11. A method of reducing the variability of the levels of bioavailability of cyclosporine for a patient in the treatment of cyclosporine, comprising administering by oral route the composition according to any one of the preceding paragraphs. 12. Способ введения пероральным путем фармацевтической композиции, предусматривающий пероральное введение пациенту, который нуждается в лечении циклоспорином, композиции по любому из предыдущих пунктов.12. An oral route of administration of a pharmaceutical composition, comprising orally administering to a patient in need of treatment with cyclosporine, a composition according to any one of the preceding paragraphs. 13. Применение композиции по любому из предыдущих пунктов для приготовления лекарственного средства, предназначенного для лечения и предупреждения аутоиммунной болезни или воспалительного состояния, или для лечения и предупреждения отторжения трансплантата, или для лечения множественной устойчивости к лекарствам.13. The use of a composition according to any one of the preceding paragraphs for the preparation of a medicament for the treatment and prevention of an autoimmune disease or inflammatory condition, or for the treatment and prevention of transplant rejection, or for the treatment of multiple drug resistance. 14. Способ приготовления композиции по любому из пп.1-12, предусматривающий тщательное смешение циклоспорина, этанола и других компонентов.14. A method of preparing a composition according to any one of claims 1 to 12, comprising carefully mixing cyclosporin, ethanol and other components.
RU2001133455/15A 1999-05-28 2000-05-26 Cyclosporin-containing and practically oil-free compositions RU2249461C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9912476.0A GB9912476D0 (en) 1999-05-28 1999-05-28 Organic compounds
GB9912476.0 1999-05-28

Publications (2)

Publication Number Publication Date
RU2001133455A true RU2001133455A (en) 2003-08-20
RU2249461C2 RU2249461C2 (en) 2005-04-10

Family

ID=10854362

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001133455/15A RU2249461C2 (en) 1999-05-28 2000-05-26 Cyclosporin-containing and practically oil-free compositions

Country Status (26)

Country Link
US (2) US6432445B1 (en)
EP (1) EP1181035B1 (en)
JP (1) JP2003500454A (en)
KR (1) KR20010111587A (en)
CN (1) CN1353613A (en)
AT (1) ATE291926T1 (en)
AU (1) AU765935B2 (en)
BR (1) BR0011030A (en)
CA (1) CA2371247A1 (en)
CZ (1) CZ20014214A3 (en)
DE (2) DE10084671T1 (en)
ES (1) ES2239605T3 (en)
GB (2) GB9912476D0 (en)
HK (1) HK1045642B (en)
HU (1) HUP0201372A3 (en)
IL (1) IL146186A0 (en)
MX (1) MXPA01012222A (en)
NO (1) NO20015785L (en)
NZ (1) NZ515154A (en)
PL (1) PL199591B1 (en)
PT (1) PT1181035E (en)
RU (1) RU2249461C2 (en)
SK (1) SK285471B6 (en)
TR (1) TR200103276T2 (en)
WO (1) WO2000072867A2 (en)
ZA (1) ZA200109658B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355195B (en) * 1997-01-30 2001-09-12 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
ATE404172T1 (en) 1998-12-30 2008-08-15 Dexcel Ltd DISPERSIBLE CONCENTRATE FOR ADMINISTRATION OF CYCLOSPORINE
GB9912476D0 (en) * 1999-05-28 1999-07-28 Novartis Ag Organic compounds
AR033711A1 (en) * 2001-05-09 2004-01-07 Novartis Ag PHARMACEUTICAL COMPOSITIONS
BR0215187A (en) * 2001-12-20 2004-11-16 Bernard Charles Sherman Pharmaceutical compositions comprising a cyclosporine, a hydrophilic surfactant and a lipophilic surfactant
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
WO2004082629A2 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
JP2005255677A (en) * 2004-02-12 2005-09-22 Nof Corp Cyclosporine preparation
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
JP2008514702A (en) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド Novel cyclosporine analogues and their pharmaceutical use
US7361636B2 (en) * 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
CN101171000A (en) 2005-04-12 2008-04-30 依兰药物国际有限公司 Nanoparticles and controlled release compositions comprising cyclosporine
CN101184800B (en) * 2005-04-27 2011-04-27 金斯潘控股有限公司 Surfactant for phenolic foam
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
JP2020503269A (en) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド Oral testosterone undecanoate therapy
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7012460A (en) 1970-08-22 1972-02-24
DE3225706C2 (en) 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Liquid active ingredient formulations in the form of concentrates for microemulsions
DE3315805A1 (en) 1983-04-30 1984-11-08 Bayer Ag, 5090 Leverkusen Active substance compositions
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB8903804D0 (en) 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
FR2609631A1 (en) 1987-01-15 1988-07-22 Sanofi Sa Stable liquid compositions based on biothionol
US6007840A (en) 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (en) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 Pharmaceutical composition containing cyclosporin
DE3908047A1 (en) 1989-03-13 1990-09-20 Desitin Arzneimittel Gmbh HIGH DISPERSES PHARMACEUTICAL COMPOSITION
US5266590A (en) 1989-12-11 1993-11-30 Isp Investments Inc. Cold stabilization of aqueous microemulsions of a water-insoluble agriculturally active compound
US5283229A (en) 1989-12-11 1994-02-01 Isp Investments Inc. Delivery system for agricultural chemicals
US5389688A (en) 1989-12-11 1995-02-14 Isp Investments Inc. Water based microemulsion formulations
US5110606A (en) 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
US5300529A (en) 1991-02-12 1994-04-05 Isp Investments Inc. Stable, clear, efficacious aqueous microemulsion compositions containing a high loading of a water-insoluble, agriculturally active chemical
EP0574492B1 (en) 1991-02-12 1999-05-12 Isp Investments Inc. Stabilization of microemulsions using hydrophobic acid buffers
US6022853A (en) * 1991-08-30 2000-02-08 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
GB9225540D0 (en) 1992-12-07 1993-01-27 Ici Plc Cleaning compositions
JPH06293633A (en) 1993-04-05 1994-10-21 Shin Etsu Chem Co Ltd Production of aqueous enteric emulsion
GB2278780B (en) 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
CH686761A5 (en) 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
FR2710535B1 (en) 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition for pharmaceutical or cosmetic use capable of forming a microemulsion.
DE4337041A1 (en) 1993-10-29 1995-05-04 Henkel Kgaa Process for the preparation in oil-in-water emulsions
WO1995022343A1 (en) 1994-02-17 1995-08-24 Shiseido Company, Ltd. Cyclosporin-containing emulsion composition
MY129435A (en) 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
US5691289A (en) 1994-11-17 1997-11-25 Kay Chemical Company Cleaning compositions and methods of using the same
HU215966B (en) 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Oral multiple emulsion-preconcentrate containing cyclosporin
JPH11505257A (en) 1995-05-19 1999-05-18 アボツト・ラボラトリーズ Self-emulsifying formulations of lipophilic drugs
SE9503143D0 (en) 1995-09-12 1995-09-12 Astra Ab New preparation
DE19537836A1 (en) 1995-10-11 1997-04-17 Henkel Kgaa Preparation of oil-in-water aerosol emulsion using emulsifier
KR970064620A (en) 1996-03-05 1997-10-13 임성기 Cyclosporin-containing external-use pharmaceutical composition
DE19615271A1 (en) 1996-04-18 1997-10-23 Huels Chemische Werke Ag Detergent containing detergents in the form of a microemulsion
KR980008239A (en) 1996-07-26 1998-04-30 김충환 Cyclosporin-containing pharmaceutical composition
GB2355195B (en) * 1997-01-30 2001-09-12 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
DK0969856T3 (en) * 1997-03-12 2005-05-02 Abbott Lab Hydrophilic binary systems for the administration of cyclosporine
CA2283780A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
US6063762A (en) 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
KR100300251B1 (en) 1997-12-05 2001-10-29 김용규 Cyclosporine-containing pharmaceutical composition
US6028067A (en) 1997-12-05 2000-02-22 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
WO1999029316A1 (en) 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
NZ329929A (en) * 1998-03-09 1999-10-28 Bernard Charles Sherman Pharmaceutical emulsion preconcentrate containing cyclosporin in a solvent system containing glycerides, propylene or polyethylene glycol, a surfactant and a co-surfactant
ATE404172T1 (en) * 1998-12-30 2008-08-15 Dexcel Ltd DISPERSIBLE CONCENTRATE FOR ADMINISTRATION OF CYCLOSPORINE
GB9912476D0 (en) 1999-05-28 1999-07-28 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
RU2001133455A (en) Essentially oil-free compositions comprising cyclosporin
RU2143919C1 (en) Pharmaceutical composition, product of transesterification of corn oil with glycerol and method of its preparing
RU2126263C1 (en) Pharmaceutical composition containing cyclosporin derivative and a method of its preparing
KR102193214B1 (en) Omega-3 fatty acid ester compositions
CA2145242C (en) Oral pharmaceutical preparation
KR100978836B1 (en) Novel Cyclosporine Analog Microemulsion Preconcentrates
KR100342942B1 (en) Oral micro-emulsion composition comprising Carduus marianus extract or silybin isolated therefrom
RU2249461C2 (en) Cyclosporin-containing and practically oil-free compositions
JP2004517148A (en) Essential N-3 fatty acids in the treatment of heart dysfunction and heart failure
JPH02255623A (en) New cyclosporine formulation
TW200422057A (en) Composition in form of emulsion or microemulsion pre-concentrate for oral administration and its uses
IE883378L (en) Capsule containing nifedipine
JPS58134031A (en) Dihydrocyclosporin d for treating multiple screlosis
US6696413B2 (en) Pharmaceutical preparation with cyclosporin A
AU762963B2 (en) Cyclosporin solution
JP2007509136A (en) Oral microemulsion composition comprising biphenyldimethyldicarboxylate and silybin
JP3748912B2 (en) High concentration solution formulation of aureobasidins
AU741923B2 (en) Pharmaceutical compositions
KR101819310B1 (en) Pharmaceutical composition comprising cyclosporine
AU745008B2 (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
US20060217320A1 (en) Soft gel formulations for saquinavir
JPS6328047B2 (en)
WO1997027850A1 (en) Compositions including amiodarone and betaxolol
JP2005255677A (en) Cyclosporine preparation
KR20170078972A (en) Pharmaceutical composition comprising cyclosporine